Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

NCT05359263 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

222

Enrollment

OTHER

Sponsor class

Conditions

Chronic Kidney Diseases

Interventions

DRUG: Dapagliflozin 10 mg
DRUG: Placebo

Sponsor

Tor Biering-Sørensen